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PEMBANGUNAN REKOMBINAN Mycobacterium smegmatis (MS) YANG 
MENGEKSPRES EPITOP-EPITOP SEL B DAN SEL T DARIPADA 
ANTIGEN BERKAITAN LATENSI Mycobacterium tuberculosis (MTB) 
SEBAGAI CALON VAKSIN TB 
 
ABSTRAK 
 Tuberkulosis (TB) masih lagi menjadi masalah kesihatan yang utama di dunia. 
Hampir satu pertiga daripada penduduk dunia dijangkiti Mycobacterium tuberculosis 
(MTB) secara laten dan 5 - 10 % daripada individu yang dijangkiti akan mendapat 
penyakit TB aktif. Bacille Calmette–Guérin (BCG) sangat berkesan dalam 
melindungi penyakit TB pada kanak-kanak, tetapi gagal untuk menghalang TB laten 
atau pengaktifan semula penyakit TB pada orang dewasa. Oleh itu, pembangunan 
vaksin TB yang berkesan menjadi keutamaan dalam usaha untuk mengawal penyakit 
ini daripada bertambah buruk. Pengekspresan antigen MTB dalam Mycobacterium 
smegmatis (MS) adalah salah satu strategi yang berpotensi untuk pembangunan 
vaksin generasi baru terhadap TB. Tesis ini mengkaji proses penghasilan dan menilai 
tahap immunogenisiti rekombinan MS (rMS) dalam mencit Balb/C yang 
mengandungi epitop sel B dan sel T daripada Antigen Berkaitan Latensi (LAA) 
MTB (Rv2005c, Rv2031c, Rv3130c, Rv3127) (rMS081). Kapasiti rMS081 untuk 
mendorong tindak balas imun humoral dan selular khusus terhadap epitop sel B dan 
sel T telah dikaji. Jumlah Imunoglobulin G (IgG) spesifik menunjukkan peningkatan 
signifikan terhadap semua epitop LAA dalam serum mencit yang diimunisasi dengan 
rMS081 berbanding kumpulan mencit kawalan. Tiada peningkatan ketara dalam 
penghasilan sitokin Interferon-gamma (IFN-), Interleukin (IL)-2 dan IL-4 terhadap 
epitop LAA dalam mencit yang diimunisasi dengan rMS081 berbanding kumpulan 
kawalan. Hasil daripada kajian ini dapat menyokong penilaian masa depan rMS081 
sebagai calon vaksin terhadap TB. 
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DEVELOPMENT OF RECOMBINANT Mycobacterium smegmatis (MS) 
EXPRESSING B- AND T-CELL EPITOPES OF LATENCY ASSOCIATED 
ANTIGENS OF Mycobacterium tuberculosis (MTB) AS A TB VACCINE 
CANDIDATE 
ABSTRACT 
Tuberculosis (TB) remains a major public health problem worldwide. Nearly one-
third of the world population is latently infected with Mycobacterium tuberculosis 
(MTB) and 5 - 10 % of infected individuals will develop active disease during their 
life time. Bacille Calmette–Guérin (BCG) efficiently protects against severe disease 
manifestations in children, but does not prevent the establishment of latent TB or 
reactivation of TB pulmonary disease in adult life. Therefore, in order to control this 
scourge from exacerbating, the development of an effective TB vaccine is an urgent 
priority. The expression of MTB antigens in Mycobacterium smegmatis (MS) is one 
of the potential strategies for the development of new generation vaccines against 
TB. This study focused on the construction and evaluation of immunogenicity in 
Balb/C mice of a recombinant MS (rMS) expressing B- and T-cell epitopes of 
Latency-Associated Antigens (LAA) (Rv2005c, Rv2031c, Rv3130c, Rv3127) of 
MTB (rMS081). The capacity of rMS081 to induce specific humoral and cellular 
immune responses against expressed B- and T-cell epitopes was evaluated. Total 
specific Immunoglobulin G (IgG) showed a significant increase against all epitopes 
(Rv2005c, Rv2031c, Rv3130c, Rv3127) in the sera of rMS081-immunized mice 
compared with the control group. In the experimental conditions evaluated, there 
were no significant increase in the cytokines, Interferon-gamma (IFN-), Interleukin 
(IL)-2 and IL-4 against the LAA epitopes in the rMS081-immunized mice compared 
with the control group. The results obtained support the future evaluation of rMS081 
as a vaccine candidate against TB in challenge studies.  
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CHAPTER 1 
LITERATURE REVIEW 
1.1 Tuberculosis (TB) 
TB is still a major infectious disease threat to humans worldwide. Globally, 
approximately 9.6 million of new TB cases were recorded and 1.5 million of TB deaths 
occurred in 2014 (WHO, 2015). Mycobacterium tuberculosis (MTB) can persist within 
the human host for years without showing disease symptoms, a condition known as latent 
TB. It caused latent infection in more than one-third of the world population (WHO, 
2015). The high prevalence of latent TB infection (LTBI) is one of the main factors that 
contribute to the increasing incidence of active TB. Thus, research on how MTB 
establishes a latent metabolic state and the development of new methods to eliminate 
LTBI are priorities for the future control of TB.  
1.2 Global incidence of TB  
WHO reported that the decreasing rate per year was 1.5 % between 2000 and 2013 and 
started to fall, 2.1 % between 2013 and 2014, achieving the Millennium Development 
Goals (MDG) target ahead of 2015 (WHO, 2015). According to the WHO TB report 
2014, most of the cases occurred in Asia (58 %) and Africa (28 %), followed by Eastern 
Mediterranean (8 %), Europe (3 %) as well as other Regions in the Americas (3 %). In 
2014, WHO also reported six countries that showed the highest TB cases were India (2.2 
million), Indonesia (1.0 million), China (0.93 million), Nigeria (0.57 million), Pakistan 
(0.5 million) and South Africa (0.45 miilion). Figure 1.1 shows the estimated number of 
new TB cases in 2014. 
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Figure 1.1 Estimated number of new TB cases in 2014 worldwide (WHO 
Tuberculosis Report, 2015). 
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On the contrary, the high income countries including most countries in Western Europe, 
the United States of America, Canada, New Zealand, Japan and Australia were recorded 
the lowest incidence rate (< 10 cases/ 100 000 population per year) (WHO, 2015). 
Several factors that are related to high TB burden including co-infection with HIV, 
poverty, homelessness, imprisonment, immigration and ineffective TB control 
programmes (Joan et al., 2010).  
1.3 TB in Malaysia 
TB in Malaysia is still a major health problem and the number one cause of death in the 
early 1940s and 1950s (Iyawoo, 2004). According to the Ministry of Health Malaysia 
(MOH), TB cases recorded a steady increase from 2007 to 2012 (Table 1.1). The 
mortality rate was 5.3 - 5.8 deaths for every 100,000 population (Benedict, 2014). 
Approximately 16,918 TB cases were recorded and responsible for 1,504 dealths in 2007, 
and increasing number of TB cases were recorded in 2012 with 22,710 cases and 1,520 
deaths. Sabah recorded the highest number of TB cases in 2012 (4,426 cases), followed 
by Selangor (3,560 cases) and Sarawak (2,430). The influx of immigrants especially from 
the TB burden country like Indonesia, Myanmar, Cambodia, Vietnam and Philiphines, is 
one of the contributing factors for the rise in the number of TB cases in the country 
(Benedict, 2014). MOH also reported that approximately 13.9 % of TB cases in Malaysia 
were discovered among the immigrant population (MOH, 2012). 
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Table 1.1 TB cases and deaths in Malaysia, 2007 to 2012 (Benedict, 2014). 
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1.4 MTB 
Mycobacterium belongs to the Mycobacteriaceae family in the Actinobacteria phylum. 
MTB is a Gram-positive bacterium. It has straight or slightly curved rod-shaped, non-
motile and non-spore forming bacterium. It has 2-4 m in length and 0.3-0.6 m in 
diameter (Iseman, 2000; Todar, 2012). Figure 1.2 shows the image of MTB bacillus 
under scanning electron micrograph. It has a complex cell wall and composed of 
glycolipids, peptidoglicans, peptide side-chains and mycolic acids (Todar, 2012). It has 
4,411,529 base pairs (bp) genome and 3924 predicted protein-coding sequence (Cole et 
al., 1998). The MTB genome was successfully sequenced and was published in 1998. 
MTB has a high content of guanine (G) and cytosine (C) in its DNA (65.6%).  The high 
GC content may be one of the survival strategies employed by the bacterium, since 
stability of DNA increases directly with number of GC bonds (Cole et al., 1998).  
1.5 Symptoms of TB 
The most common MTB infection is in the lungs, known as pulmonary TB. People with 
pulmonary TB have symptoms like cough, weakness, chest pain, bloody sputum 
(hemoptysis), and may develop severe breathing problems. TB patients also commonly 
have symptoms such as fever, cough, malaise, night sweats and loss of appetite and 
weight. TB can also affect other parts of body, including, lymph nodes, kidneys, spine or 
brain, gastrointestinal tract, bones and others, resulting in extra pulmonary TB (EPTB). 
The symptoms of EPTB are depending on which area of the body is infected. If TB 
infected the lymph nodes, it can cause swollen glands and a painless red mass, usually at 
the sides and base of the neck. It also can cause paralysis if it infected the spinal cord.  
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Figure 1.2 Scanning electron micrograph of MTB bacillus. 
(The picture was taken from Todar (2012) [Online]. Available from: http://textbookof 
bacteriology.net/tuberculosis.html). 
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1.6 Transmission and pathogenesis of TB 
A deep understanding of the transmission and pathogenic mechanisms of MTB infection 
and colonization of susceptible hosts is crucial to the vaccine developments and 
treatments for TB. The most frequent route of MTB infection is via airborne 
transmission. TB can spread to other people through coughing, sneezing, talking or 
singing when the person inhales air containing the droplet nuclei (McNerney et al., 
2012). The droplet nuclei of the bacteria entering the body through mouth or nasal 
passages, upper respiratory tract, bronchi and reach the alveoli of the lungs. A cascade of 
host defense mechanisms is triggered when a small number of inhaled MTB reach the 
terminal airspaces of the lungs and are ingested by alveolar macrophages (Orme, 2014). 
 In lungs, MTB infects macrophages, B- and T-lymphocytes, natural killer cells (NK), 
neutrophils, dendritic cells (DCs),  T cells and other cells to initiate the formation of 
granuloma (Figure 1.3). The granuloma may provide a local environment for interactions 
of innate and adaptive immune system components (Pitt et al., 2013). Infection does not 
necessarily lead to TB disease, only 3-10 % of infected individuals will develop the 
disease during their life-time, while more than 90 % of the infected individuals sustain 
the bacteria in latent state. Bacteria inside the granuloma can become dormant or latent, 
resulting in LTBI. The lifetime risk for immunocompetent individuals is estimated at 
around 5-10 %, whereas the risk of reactivation for immunocompromised, HIV-infected 
individual is around 10 % annually (Smith & Ross, 1994).  
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Figure 1.3 Diagram of TB infection and transmission (Tang et al., 2016).  
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1.7 Immunity to TB  
The immune response is composed of innate and adaptive immune response that are 
responsible to maintain immune homeostasis against any infections. The interaction 
between MTB and host cells is complex because MTB is sophisticated mycobacteria and 
can survive inside host cells (Coler et al., 2001).  
1.7.1 Innate immunity  
Innate immune response is a form of natural immunity in which the immune cells have 
never encountered the pathogen, but can nevertheless eliminate it. Innate immune system 
comprised of the anatomical barriers, the complement system, macrophages, DCs, 
granulocytes and NK cells. The innate response mainly controlled by macrophages and 
neutrophils. Macrophages are involved in phagocytosis of MTB and kill the bacteria by 
production of reactive oxygen and nitrogen species. Other cells, neutrophils are recruited 
into the infection / inflammation sites when inflammatory signals are triggered (Urban, 
2006).  
NK cells are large granular CD3−CD56+ lymphocytes, constituting approximately 10 % 
of peripheral blood lymphocytes. The vast majority of NK cells (90-95 %) are cytotoxic 
and do not produce Interferon-gamma (IFN-. Only 5-10 % of NK cells are IFN- 
producing cells. It can mediate protection through elimination of MTB infected cells and 
by secretion of cytokines that activate the adaptive immune response. It is also involved 
in optimizing the capacity of CD8+ T cells to produce IFN- and to lyse infected cells 
(Vankayalapati & Barnes, 2009). 
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Another important step in host innate responses is the recognition of MTB products on 
macrophage and DCs by Toll-like receptors (TLR) (Belvin & Anderson, 1996; 
Medzhitov et al., 1997; Visintin et al., 2001). There are four TLRs involved in 
recognition of MTB namely TLR2, TLR4, TLR8 and TLR9 (Quesniaux et al., 2004; 
Zhang et al., 2004). TLR2 is involved in detection of the mycobacterial glycolipids like 
lipoarabinomannan (LAM) (Means et al., 1999b; Underhill et al., 1999) and MTB 
lipoprotein, 19 kDa (Brightbill et al., 1999; Noss et al., 2001). TLR4 functions in 
inflammatory responses in chronic TB infections (Fremond et al., 2003).  
1.7.2 Adaptive immunity 
1.7.2.1 Cellular immune response 
Cell mediated immune response is important to control MTB infection. CD4+ T cells and 
CD8+ T cells are two important subsets of T cells to control TB. CD4+ T cells recognize 
antigens via Major Histocompatibility Complex (MHC) class II molecules, while CD8+ 
T cells recognize antigens presented by MHC class I. CD4+ T cells play an important 
role in removing infected APC, while CD8+ T cells can directly eliminate MTB infected 
cells and intracellular pathogen (Silva et al., 2000; Tang et al., 2016). Type 1 CD4+ 
helper T (Th1) cells secrete IFN- Tumor Necrosis Factor- (TNF-and Interleukin-2 
(IL-2)to recruit and activate T cells (Prezzemolo et al., 2014). In turn, the cytokines will 
react with activated macrophages in upregulation of inducible nitric oxide synthase, 
which leads to the production of ROI such as nitric oxide (NO) and RNI (O2). IFN- is 
the signature cytokine of the Th1 T cell and play role in macrophage activation. It can 
activate macrophages to become more bactericidal, producing greater quantities of ROI 
(Kaufmann, 2002).  
 11 
 
CD8+ T cells play important roles in the control of MTB infection through two pathways 
of cytolysis. Firstly, CD8+ T cells release perforin and granzymes (serine protease) to 
lyse the infected cells (Vanja et al., 2002). Secondly, CD8+ T cells lyse the target cells 
via Fas/FasL interaction, resulting in apoptosis or lysis of the target cells (Vanja et al., 
2002). Another subset of CD4+ T cells, Th17 may produce IL-17, which can trigger the 
recruitment of neutrophils in control TB (Tang et al., 2016). On the other hand, the 
unconventional  T cells and CD1-restricted T cells may also play role in TB control 
(Tang et al., 2016).  T cells can recognize the components of MTB such as glycolipid 
to control TB (Tang et al., 2016). CD1 T cells play an important role in protection against 
microbial pathogens that contain lipids on their cell walls or membranes (Jayawardena et 
al., 2001; Chiu et al., 2002; Van et al., 2004). 
1.7.2.2  Humoral immune response  
B cells play important role in the regulation of the host response to MTB. B cells can 
produce antibodies which could functions in multiple aspects of both innate and adaptive 
immune response (Figure 1.4). These antibodies can bind specifically to the pathogens 
and neutralize or eliminate the pathogens from the body (Abbas & Lichtman, 2003). 
Antibody responses to MTB may have different roles based on the stages of infection and 
diseases. First, in primary progressive TB, for example in children under two years of 
age, levels of specific antibodies are low due to the paucibacillary nature of the disease 
and the associated low antigen burden, to the immaturity of the child’s immune system, 
or to both (Shajo et al., 2010).  
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During latent infection, a small number of tubercle bacilli persist inside granulomas 
where bacillary multiplication is restricted by the host immune response. During this 
state, some bacterial proteins may induce measurable levels of antibody. As preclinical 
disease, some bacterial proteins may induce antibody responses before clinical 
manifestations appear due to their relative immunodominance and / or increased 
production. Reactivation tends to be associated with a gradual increase in serum levels of 
Immunoglubulin (Ig) G antibody, which is detected in at least 90 % of reactivation 
disease patients (Lyashchenko et al., 1998; Shajo et al., 2010). 
The B cells could also function as APC to interact with T cells (T follicular helper cells) 
at the germinal centre (GC) (Chan et al., 2014). Besides that, B cells may produce the 
proinflammatory cytokines, TNF-and IL-6 and reduce production of cytokine IL-10 
(Chan et al., 2014). Antibodies can also form immune complex that fix complements and 
modulate the inflammation in infected tissues (Chan et al., 2014).  
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Figure 1.4  Mechanisms by which B cells shape the immune response to MTB (Chan 
et al., 2014). 
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1.8 Control of TB 
1.8.1 Diagnosis of TB  
Rapid and accurate detection of MTB is very important for TB control. The primary 
method of examination for TB patient with symptoms is using sputum smear microscopy. 
However, this method is time consuming and has high contamination rate. According to 
WHO guideline, the sputum samples must be taken at least two or three slides per patient 
on successive days (two days) and the results must show positive acid-fast bacilli (AFB) 
to comfirm the infection (WHO, 2013). To date, microscopic system using TBDx 
automated system (Signature Mapping Medical Sciences, Herndon, VA, USA) has been 
implemented in TB diagnosis. This technology will be able to detect and diagnose MTB 
sputum smear automatically, it save time, more effective and safer than previous 
diagnosis (Cheon et al., 2016). However, the most accurate and sensitive method in TB 
diagnosis is culture method. It was used as a gold standard technique in diagnosis of 
active TB. Moreover, there are several new liquid culture system such as Bactec MGIT 
960 (BD Diagnostics, USA) and BacT/Alert MB (bioMerieux, France). These systems 
have higher sensitivity and decrease time of diagnosis compared to the conventional 
method (Cheon et al., 2016). 
The additional diagnosis such as chest radiograph, Tuberculin skin test (TST) and 
Interferon-gamma release assays (IGRAs) are used to comfirm the diagnosis of TB. The 
chest radiograph is additional diagnosis especially for the acute pulmonary TB disease. 
Primary pulmonary TB typically has a number of abnormalities and reveals hilar 
lymphadenopathy in the lung (Jeong & Lee, 2008) (Figure 1.5). TST and IGRAs are the 
widely used methods for diagnosing active TB and LTBI. The TST was performed by 
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injecting a small amount of purified protein derivative (PPD) into the skin of the forearm. 
After 48-72 hours of injection, the diameter of induration on the arm is measured (Figure 
1.6). If the diameter of induration is larger than or equal to 10 mm, it is considered a 
positive reaction (Froeschle et al., 2002). IGRAs are in vitro blood test for detection of 
MTB antigens. The IGRAs were developed based on immunological mechanisms 
between host antigen-specific T cells and MTB antigens (ESAT-6, CFP-10), which 
resulting in secretion of IFN-, a pro-inflammatory cytokine (Whitworth et al., 2013). 
Two types of IGRAs are currently available in the cilinical practice for TB diagnosis, 
namely T-SPOT.TB test (Oxford Immunotech, Oxford, UK) and QuantiFERON Gold In-
tube (GFT-GIT, Cellestis, Victoria, Australia) (Figure 1.7). For the T-SPOT.TB test, the 
results are based on the measurement of the number of IFN-spots obtained, while for 
GFT-GIT test, the results are based on the concentration of IFN-released is determined 
by ELISA (Cheon et al., 2016).  
Molecular diagnosis using Nucleic Acid Amplification Test (NAAT) is a sensitive 
method that can produce a much faster result than conventional methods for diagnosis of 
TB infection and drug resistance detection (Dheda et al., 2013). The most common 
amplification techniques widely used is Polymerase Chain Reaction (PCR) (WHO, 
2006). Besides, there are other commercially available NAAT methods for TB diagnosis 
such as Xpert MTB/RIF (Cepheid, USA), PURE-TB-LAMP (Eiken Chemical, Japan), 
and Genotype MTBDRsl (Hain Lifescience, Germany) (Cheon et al., 2016). The Xpert 
MTB/RIF is the most advanced tool and was recommended by WHO as initial diagnosis 
test for patients with HIV or MDR-TB are suspected (Cheon et al., 2016).  
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Figure 1.5 Primary TB manifesting primarily lymphadenopathy. Posteroanterior chest 
radiograph shows right hilar mass (arrow). Note smaller nodule 
(arrowhead) in right upper lung zone (Jeong & Lee, 2008). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.6 TST: The size of induration is measured 48-72 hours after injection (CDC, 
2015). 
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Figure 1.7 Immunological basis of TST and IGRAs. (A) Upon TB infection,  
 presentation of antigens by APCs to priming of antigen-specific T cells. 
(B) TST used to detect a hypersensitivity reaction in vivo following 
intradermal injection of TB antigens. (C, D) IGRAs detect a T cell IFN- 
response in vitro following overnight stimulation of PBMCs or whole 
blood with TB antigens (Whitworth et al., 2013). 
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1.8.2 Treatment of TB  
Drug treatment is fundamental for controlling TB. The objectives of treatment are to cure 
TB patients and to break the transmission of TB as well as to prevent of a possible 
relapse. Drug treatment started in 1944 with streptomycin (SM) and paraaminosalicylic 
acid (PAS). In 1952, isoniazid (INH) was combined to the previous drugs, resulting in 
improving the efficacy of treatment but the treatment still administered for 18-24 months. 
In 1960, ethambutol (ETH) was introduced to substitute PAS, and the treatment was 
shortened to 18 months. Then, rifampicin (RIF) was introduced in the 1970’s into the 
combinations, resulting in the treatment was shortened to just nine months. Finally, in 
1980, pyrazinamide (PZA) was introduced into the treatment, which reduced treatment 
further to only six months (Friedman, 2000).  
An initial TB treatment should receive all four drugs namely INH, RIF, PZA and ETH. 
Two drugs (INH and RIF) should be administered over the course of the six months of 
treatment, and the other two drugs (PZA and ETH) should be administered for the first 
two months or until the bacilloscopy results are negative (Caminero et al., 2015). The 
drugs should be taken on an empty stomach in the morning. Noncompliance with the 
treatment compromises the curing process and induced drug resistance (Caminero et al., 
2015).  
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1.8.3 Prophylaxis 
1.8.3.1 BCG 
BCG vaccine was developed more one hundred years ago (between 1908 and 1920) by 
two French scientists, Albert Calmette and Camille Guerin at the Institute Pasteur in 
Lille, France. The M. bovis strain became attenuated and lost the virulence after 
underwent 231  serial passages (Mahairas et al., 1996; Behr et al., 1999; Gordon et al., 
1999; Brosch et al., 2001). In July 1921, the BCG was successfully administered on 
newborn child with no harmful effect. From then on, BCG was widely used in children 
and was promoted by WHO in 1974.  
BCG is the only licenced TB vaccine that currently used in many countries worldwide. 
The BCG protection is greater when it is administered to neonates and children (up to 80 
%), but only 50 % of adults are protected (Colditz et al., 1994; Dietrich et al., 2003). 
There are several factors that contributing to the failure of BCG, such as the absence of 
important genes in BCG, BCG strains used, the freeze-dried vaccine preparations, the 
genetic and age variability of the vaccines, the influence of environmental mycobacteria 
strains, latent MTB infection in vaccinees and the different routes of administration 
(Colditz et al., 1994; Lagranderie et al., 1996; Fine et al., 1999; Brandt et al., 2002; 
Eddine & Kaufmann 2005; Norazmi et al., 2005). 
1.8.3.2 Development of new generation vaccines against TB 
Several approaches and strategies are applied in developing more effective and safer 
vaccines than BCG. There are three approaches adopted by vaccine designers; i) 
replacing the BCG antigen with long-term protection genes; ii) preparing BCG vaccinees 
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with booster; and iii) developing novel therapeutic TB vaccines. So, there are several 
vaccine strategies currently developed and are being tried based on these approaches.  
1.8.3.2.1 BCG replacements 
1.8.3.2.1.1 Recombinant BCG (rBCG) strains  
The first rBCG vaccine, rBCG30 was constructed by modification of BCG by inserting of 
plasmid pMBT30 into BCG (Horwitz et al., 2000; Principi & Esposito, 2015). The 
vaccine was developed in order to over-express the secretion of Ag85B in host immune 
system. The phase 1 clinical trial completed with good protection without major adverse 
effects in animal models. However, the vaccine was unable to continue for further 
development due to an antibiotic resistance problem (Costa et al., 2014). 
The second recombinant BCG vaccine was VPM1002 (ureCHly+rBCG) (Principi & 
Esposito, 2015). Some modifications were made to the BCG genome. The gene encoding 
for listeriolysin (Hly) of Listeria monocytogenes was integrated into the BCG genome, 
inactivation of urease C (ureC) and the insertion of hygromycin resistance genes. Phase I 
clinical trial has been completed and the phase IIa clinical trial in infants is ongoing 
(Grode et al., 2013; Principi & Esposito, 2015). 
1.8.3.2.1.2 Live attenuated MTB strains 
MTBVAC01 was constructed by inactivated of PhoP and fadD26 genes of MTB strain to 
increase safety (Perez et al., 2011). In preclinical studies demonstrated that it is safe and 
confer a protection against TB infection (Arbues, 2013). The vaccine is entering phase 1 
clinical trial (Principi & Esposito, 2015). 
 21 
 
1.8.3.2.2 Booster vaccines 
1.8.3.2.2.1 Viral vectored vaccines 
MVA85A was constructed by modification of Vaccinia Ankara virus expressing Ag85A, 
as a heterologous booster for the BCG vaccine (McShane et al., 2004). In phase 1 clinical 
trial it was safe and well tolerated (McShane et al., 2004). Phase IIb clinical trial was 
conducted in South Africa (Tameris et al., 2013). Although the trial showed MVA85A 
was safe, it elicited only moderate immune response and no significant protection against 
MTB infection (Tameris et al., 2013). 
Another viral vectored vaccine is Aeras 402 (Crucell Ad35), which contains Ag85A, 
Ag85B and TB10.4 (Radosevic et al., 2007; Capone et al., 2013). In phase I clinical trial, 
Aeras 402 was shown to significantly protect mice and in humans and safely induce CMI 
responses (Radosevic et al., 2007; Abel et al., 2010). Phase II clinical trial in children is 
ongoing (Principi & Esposito, 2015).  
1.8.3.2.2.2 Protein-adjuvanted vaccines 
M72F is a subunit vaccine containing Ag32A and Ag39A (Leroux-Roels et al., 2013). It 
was delivered with AS01 (liposomes, MPL and QS21) as adjuvant, which induced the 
highest vaccine-specific responses (Leroux-Roels et al., 2013). In phase I/IIa trials, it was 
safe and stimulates CMI responses (Day et al., 2013). Phase IIb clinical trial is ongoing 
(Tang et al., 2016). 
Hybrid 1/IC31 is a combination with Hybrid 1 (Ag85B-ESAT-6) and IC31 as adjuvant. 
Phase I clinical trial was completed and phase IIa clinical trial is ongoing (van Dissel et 
al., 2010; van Dissel et al., 2011). HyVac4/Aeras-404 vaccine was constructed by 
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combination of Ag85B and TB10.4. Phase II clinical trial HyVac4 in adjuvant with IC31 
is ongoing (Lee et al., 2014). Hybrid 56/AERAS-456 vaccine was generated from the 
combination of Ag85B-ESAT-6 and Rv2660c. The vaccine shows better protection than 
H1 and BCG when in adjuvant with CAF01 (Aagard et al., 2011). The vaccine is ongoing 
in phase IIa clinical trial (Tang et al., 2016). 
1.8.4 Therapeutic vaccines 
1.8.4.1 RUTI 
RUTI is an inactivated vaccine that composed of detoxified, fragmented MTB cells and 
delivered in liposomes (Cardona et al., 2006). The vaccine was used as therapeutic 
vaccine to shorten the treatment of active TB disease and LTBI (Cardona et al., 2006). 
Phase IIa clinical trial was completed. It was safe and no systemic adverse events and few 
local side effects consisting of minor pain (Groschel et al., 2014).  
1.8.4.2 Mycobacterium vaccae (Mv) 
Mv vaccine was generated by heat-killed whole Mv become an immunotherapeutic 
vaccine against TB. The mycobacterium contains antigens such as Hsp71, Hsp65, LAM 
and 40 kDa secreted antigens (Collins et al., 1983). In phase I/II clinical trials, it could 
boost BCG-primed host immunity and improve clinical symptoms of treatment-naïve TB 
patients (Vuola et al., 2003; Yang et al., 2011). Phase III clinical trial is still ongoing 
(Tang et al., 2016). 
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1.8.4.3 Mycobacterium indicus pranii (MIP) 
MIP is an immunotherapeutic vaccine that was generated by heat-inactivated whole MIP. 
It was first developed as a vaccine against leprosy. It also showed protection and induced 
T cell responses better than BCG in animal models (Gupta et al., 2009). Phase III clinical 
trial was completed in India but the results not yet published (Tang et al., 2016).  
1.9 Reverse Vaccinology (RV) 
RV is an approach based on in silico prediction of vaccine antigen candidates using 
genetic sequences rather than the pathogen itself. This method is applied to identify in 
silico the complete repertoire of immunogenic antigens without the need of culturing the 
microorganism. There are three main approaches that have been applied in mining the 
whole MTB genome 3989 ORFs products and down-selecting the number of antigens to 
be tested in animal models as vaccine candidates. The first approach led by Anne de 
Groot, used an in silico screening approach with EpiMatrix consisting of the entire MTB 
coding genome for human MHC class I and class II epitopes (Groot, 2001). Second 
approach was concentrated on antigen discovery 16 genomic regions of MTB are deleted 
or lacking in BCG (Attiyah, 2008). Finally, several studies reported the identification of 
novel vaccine candidates following in silico selection, expression as DNA or recombinant 
protein, and in vivo testing for immunogenicity and protective efficacy (Zvi, 2008).   
1.10 Mycobacterium smegmatis (MS) 
MS is a non-pathogenic mycobacterium and has been successfully used as a vaccine 
adjuvant in the prevention and treatment of MTB (Guo et al., 2012). The safety and 
reliability of vectored vaccine have been documented (Yang et al., 2009). MS grows 10 
times faster than BCG and the MTB-associated proteins expressed by MS are identical to 
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the natural MTB proteins in terms of biochemical and immunological properties (Zhang 
et al., 2010). MS is also rapidly destroyed by phagolysosomal protease in the 
phagosomes of infected cells, helping in rapid uptake of expressed antigens in MS (Luo 
et al., 2000; Kuehnel et al., 2001). Single inoculation of the MS live vaccine has been 
shown to provoke sustained induction of target antigens. rMS live vaccine generated by 
sub-cloning exogenous genes can be used for the treatment of MTB infection. The 
underlying mechanisms of rMS therapy include restoration of protective immunity, 
increased generation of H2O2 and nitric oxide by monocyte-macrophage cells, and a shift 
of the immune response from Th2 type to Th1 type (Yi et al., 2007; Garberi et al., 2011). 
These changes may facilitate clearance of MTB, particularly the drug resistant MTB (Yi 
et al., 2007; Garberi et al., 2011).  
1.11 LAA 
There are about 50 LAA which belong to the DosR regulon, which control the expression 
of these proteins during latency (Singh, 2014). Many of them are believed to be good T 
cell antigens, but the functions of most of their encoded proteins are still unknown. Their 
functions are categorized into several categories, such as redox balance, metabolism and 
energy, cell wall and membrane proteins, stress proteins, host-pathogen interactions and 
hypothetical proteins. In this study, two genes Rv2005c and Rv2031c belong to stress 
proteins, Rv3130c belongs to redox balance, metabolism and energy, and Rv3127 
belongs to nitrogen metabolism (Singh, 2014). Many studies performed to investigate the 
potential LAA as vaccine candidates. The most common LAA used as vaccine candidates 
is Rv2031c (HspX or -crystallin). It can induce both active and latent infection and 
generates humoral and CMI response (Singh, 2014).  
